Advances in the Diagnosis of Neuroendocrine Neoplasms

Somatostatin receptor PET/CT using 68Ga-labeled somatostatin analogs, is a mainstay for the evaluation of the somatostatin receptor status in neuroendocrine neoplasms. In addition, the assessment of glucose metabolism by 18F-FDG PET/CT at diagnosis can overcome probable shortcomings of histopathologic grading. This offers a systematic theranostic approach for the management of neuroendocrine neoplasms, that is, patient selection for the appropriate treatment —surgery, somatostatin analogs, peptide receptor radionuclide therapy, targeted therapies like everolimus and sunitinib, or chemotherapy—and also for therapy response monitoring.
Source: Seminars in Nuclear Medicine - Category: Nuclear Medicine Authors: Source Type: research